BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019; 11(1): 50-64 [PMID: 30705718 DOI: 10.4254/wjh.v11.i1.50] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Lee S, Oh J, Lee K, Cho M, Paulson B, Kim JK. Diagnosis of Ischemic Renal Failure Using Surface-Enhanced Raman Spectroscopy and a Machine Learning Algorithm. Anal Chem 2022;94:17477-84. [PMID: 36480771 DOI: 10.1021/acs.analchem.2c03634] [Reference Citation Analysis]
2 Zhu Y, He J, Luo X. Prognostic Value of Computed Tomography Texture Features in Patients with Hepatocellular Carcinoma Following Stereotactic Ablative Radiotherapy. Iran J Radiol 2022;19. [DOI: 10.5812/iranjradiol-118338] [Reference Citation Analysis]
3 Shi L, Qu Z, Yang Y, Zhang Y, Sun D. Analysis of Related Risk Factors of Microvascular Invasion in Hepatocellular Carcinoma. Comput Math Methods Med 2022;2022:8195512. [PMID: 35356664 DOI: 10.1155/2022/8195512] [Reference Citation Analysis]
4 Lee S, Tak E, Cho YJ, Kim J, Lee J, Lee R, Lee K, Kwon M, Yoon Y, Lee S, Namgoong J, Kim JK. Nano-biomarker-Based Surface-Enhanced Raman Spectroscopy for Selective Diagnosis of Gallbladder and Liver Injury. BioChip J. [DOI: 10.1007/s13206-022-00045-4] [Reference Citation Analysis]
5 Lee TY, Choi HJ, Ahn J, Hong TH, You Y. Efficacy of Tumor Markers After Liver Transplantation In Patients With Hepatocellular Carcinoma. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.01.007] [Reference Citation Analysis]
6 Akamatsu N, Hasegawa K, Kokudo N, Makuuchi M. Living Donor Liver Transplantation. The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases 2022. [DOI: 10.1007/978-981-19-0063-1_65] [Reference Citation Analysis]
7 Tang Y, Wang T, Ju W, Li F, Zhang Q, Chen Z, Gong J, Zhao Q, Wang D, Chen M, Guo Z, He X. Ischemic-Free Liver Transplantation Reduces the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Front Oncol 2021;11:773535. [PMID: 34966679 DOI: 10.3389/fonc.2021.773535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mouchli M, Reddy S, Gerrard M, Boardman L, Rubio M. Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article. Ann Hepatol 2021;22:100249. [PMID: 32896610 DOI: 10.1016/j.aohep.2020.08.067] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
9 Zhang Q, Jiao X. LDH and GGT/ALT Ratio as Novel Prognostic Biomarkers in Hepatocellular Carcinoma Patients after Liver Transplantation. Comput Math Methods Med 2021;2021:9809990. [PMID: 34845414 DOI: 10.1155/2021/9809990] [Reference Citation Analysis]
10 Badwei N, Monsef WA, Montasser I, Bahaa M, El Meteini M, Kamel SY. Role of inflammatory markers in predicting hepatocellular carcinoma recurrence after liver transplantation. Egypt Liver Journal 2021;11:40. [DOI: 10.1186/s43066-021-00105-8] [Reference Citation Analysis]
11 Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol 2021;9:738-48. [PMID: 34722189 DOI: 10.14218/JCTH.2021.00125] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Ozgor D, Otan E. HCC and Tumor Biomarkers: Does One Size Fits All? J Gastrointest Cancer 2020;51:1122-6. [PMID: 32827068 DOI: 10.1007/s12029-020-00485-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Wang PX, Xu Y, Sun YF, Cheng JW, Zhou KQ, Wu SY, Hu B, Zhang ZF, Guo W, Cao Y, Huang XW, Zhou J, Fan J, Yang XR. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int 2021;41:562-73. [PMID: 33205544 DOI: 10.1111/liv.14734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
14 Pravisani R, Mocchegiani F, Isola M, Lorenzin D, Adani GL, Cherchi V, De Martino M, Risaliti A, Lai Q, Vivarelli M, Baccarani U. Postoperative Trends and Prognostic Values of Inflammatory and Nutritional Biomarkers after Liver Transplantation for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:513. [PMID: 33572776 DOI: 10.3390/cancers13030513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
15 Hasan B, Colak Y, Khalid RA, Castillo M, Castaneda D, Tandon K, Shaw JJ, Erim T, Zervos XB, Castro FJ, Al-Khalloufi K. Early Detection of Hepatocellular Carcinoma Recurrence in the Posttransplant Population: A Comparison of RETREAT and Cleveland Clinic Florida Scoring System. Transplant Proc 2021;53:193-9. [PMID: 33069486 DOI: 10.1016/j.transproceed.2020.09.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Sui W, Gan Q, Liu F, Ou M, Wang B, Liao S, Lai L, Chen H, Yang M, Dai Y. Dynamic Metabolomics Study of the Bile Acid Pathway During Perioperative Primary Hepatic Carcinoma Following Liver Transplantation. Ann Transplant 2020;25:e921844. [PMID: 32572018 DOI: 10.12659/AOT.921844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pinto Marques H, Gomes da Silva S, De Martin E, Agopian VG, Martins PN. Emerging biomarkers in HCC patients: Current status. Int J Surg 2020;82S:70-6. [PMID: 32344023 DOI: 10.1016/j.ijsu.2020.04.043] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
18 Fang JZ, Xiang L, Hu YK, Yang Y, Zhu HD, Lu CD. Options for the treatment of intrahepatic recurrent hepatocellular carcinoma: Salvage liver transplantation or rehepatectomy? Clin Transplant 2020;34:e13831. [PMID: 32068916 DOI: 10.1111/ctr.13831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Sánchez Segura J, León Díaz FJ, Pérez Reyes M, Cabañó Muñoz D, Sánchez Pérez B, Pérez Daga JA, Montiel Casado C, Santoyo Santoyo J. Predictive Models of Hepatocellular Carcinoma Recurrence After Liver Transplantation. Transplant Proc 2020;52:546-8. [PMID: 32037068 DOI: 10.1016/j.transproceed.2019.11.048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol 2020;72:262-76. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 21.3] [Reference Citation Analysis]
21 Yang F, Zhang Y, Ren H, Wang J, Shang L, Liu Y, Zhu W, Shi X. Ischemia reperfusion injury promotes recurrence of hepatocellular carcinoma in fatty liver via ALOX12-12HETE-GPR31 signaling axis. J Exp Clin Cancer Res 2019;38:489. [PMID: 31831037 DOI: 10.1186/s13046-019-1480-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
22 章 文. Molecular Markers and Recurrence of Hepatocellular Carcinoma after Liver Transplantation. ACM 2019;09:310-318. [DOI: 10.12677/acm.2019.93047] [Reference Citation Analysis]